** Medical device maker Abbott Laboratories ABT.N maintained its annual profit forecast on Wednesday and said it expected U.S. tariffs to hit earnings by a "few hundred million dollars"
** Median PT of 28 brokerages covering the stock is $145 - LSEG data
OPTIMISM FOR MEDTECH
** J.P.Morgan ("overweight," PT: $135) says it is optimistic about co, citing strong fundamentals and effective management to mitigate tariff impacts
** Piper Sandler ("overweight," PT: $145) says it is confident in co's diversified business model and its ability to navigate through periods of uncertainty while delivering sustainable growth
** TD Cowen ("buy," PT: $145) sees co mitigating tariff impacts through strategic manufacturing adjustments and leveraging past successes
** "We saw ABT rapidly respond to the COVID pandemic and build a multi billion-dollar Covid testing franchise in very little time. This precedent should give investors confidence that the plant optimization initiatives can succeed in a similar fashion" - TD
** Jefferies ("hold," PT: $137) says co's ability to counteract tariff pressures is a positive surprise, following JNJ JNJ.N maintaining its guidance, which provides optimism for other medtech companies
(Reporting by Rashika Singh in Bengaluru)
((rashika.singh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.